<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle">
<p class="DocumentTitle"><strong>UROGESIC BLUE- methenamine, sodium phosphate, monobasic, methylene blue and hyoscyamine sulfate tablet, coated </strong><br>EDWARDS PHARMACEUTICALS, INC.<br></p>
<p class="disclaimer">Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. <a href="http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/EnforcementActivitiesbyFDA/SelectedEnforcementActionsonUnapprovedDrugs/default.htm">For further information about unapproved drugs, click here.</a></p>
</div>
<h1>UROGESIC-BLUE™</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-1"></a><p></p>
<p class="First"><span class="Bold">Rx Only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="section-2"></a><p></p>
<h1>Description</h1>
<p class="First">Each tablet contains:</p>
<table width="75%">
<col align="left" valign="top" width="10%">
<col align="left" valign="top" width="45%">
<col align="left" valign="top" width="45%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left"></td>
<td align="left">Methenamine, USP</td>
<td align="left">81.6 mg</td>
</tr>
<tr>
<td align="left"></td>
<td align="left">Monobasic Sodium Phosphate, USP</td>
<td align="left">40.8 mg</td>
</tr>
<tr>
<td align="left"></td>
<td align="left">Methylene Blue, USP</td>
<td align="left">10.8 mg</td>
</tr>
<tr class="Botrule Last">
<td align="left"></td>
<td align="left">Hyoscyamine Sulfate, USP</td>
<td align="left">0.12 mg</td>
</tr>
</tbody>
</table>
<p><span class="Bold">Inactive Ingredients include</span>: microcrystalline cellulose, NF, mannitol, USP, croscarmellose sodium, NF, magnesium stearate, NF and lake blend blue.</p>
<p>HYOSCYAMINE SULFATE is an alkaloid of belladonna. Exists as a white crystalline powder. Affected by light It is very soluble in water; freely soluble in alcohol; practically insoluble in ether.</p>
<p>METHENAMINE exists as colorless, lustrous crystals or white crystalline powder. Its solutions are alkaline to litmus. Freely soluble in water; soluble in alcohol and in chloroform.</p>
<p>METHYLENE BLUE exists as dark green crystals. It is soluble in water and in chloroform; sparingly soluble in alcohol.</p>
<p>MONOBASIC SODIUM PHOSPHATE exists as a white crystalline powder. Its solutions are acidic to litmus. It is freely soluble in water and practically insoluble in alcohol.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">HYOSCYAMINE is a parasympatholytic which relaxes smooth muscles and thus produces an antispasmodic effect. It is well absorbed from the gastrointestinal tract and is rapidly distributed throughout body tissues. Most is excreted in the urine within 12 hours, 13% to 50% being unchanged. Its biotransformation is hepatic. Its protein binding is moderate.</p>
<p>METHENAMINE degrades in an acidic urine environment releasing formaldehyde which provides bactericidal or bacteriostatic action. It is well absorbed from the gastrointestinal tract. 70% to 90% reaches the urine unchanged at which point it is hydrolyzed if the urine is acidic. Within 24 hours it is almost completely (90%) excreted; of this amount at pH 5, approximately 20% is formaldehyde. Protein binding: some formaldehyde is bound to substances in the urine and surrounding tissues. Methenamine is freely distributed to body tissue and fluids but is not clinically significant as it does not hydrolyze at pH greater than 6.8.</p>
<p>METHYLENE BLUE possesses weak antiseptic properties. It is well absorbed in the gastrointestinal tract and is rapidly reduced to leukomethylene blue which is stabilized in some combination form in the urine. 75% is excreted unchanged.</p>
<p>MONOBASIC SODIUM PHOSPHATE helps to maintain an acid pH in the urine necessary for the degradation of methenamine.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First"><span class="Bold">UROGESIC-BLUE™ </span>is indicated for the treatment of symptoms of irritative voiding. Indicated for the relief of local symptoms, such as hypermotility which accompany lower <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span> and as antispasmodic. Indicated for the relief of urinary tract symptoms caused by diagnostic procedures.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<p class="First"><span class="Bold">UROGESIC-BLUE™</span> is contraindicated in patients with a <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of the ingredients. Risk-benefit should be considered when the following medical problems exist: Cardiac disease (especially cardiac arrythmias, <span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">congestive heart failure</span>, coronary heart disease, <span class="product-label-link" type="condition" conceptid="315273" conceptname="Mitral valve stenosis">mitral stenosis</span>); gastrointestinal tract obstructive disease; <span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">glaucoma</span>; <span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">myasthenia gravis</span>; acute <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> may be precipitated in <span class="product-label-link" type="condition" conceptid="194406" conceptname="Urinary tract obstruction">obstructive uropathy</span> (such as <span class="product-label-link" type="condition" conceptid="433813" conceptname="Bladder neck obstruction">bladder neck obstruction</span> due to <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>).</p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">Do not exceed recommended dosage. If rapid pulse, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, or <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurring of vision</span> occurs<span class="Bold"> discontinue use immediately.</span></p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.1"></a><p></p>
<h2>Cross sensitivity and/or related problems</h2>
<p class="First">patients intolerant of belladonna alkaloids may be intolerant of this medication also.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="section-7.2"></a><p></p>
<h2>Pregnancy/Reproduction</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.2.1"></a><p></p>
<h3>(Pregnancy Category C)</h3>
<p class="First">hyoscyamine and methenamine cross the placenta. Studies have not been done in animals or humans. It is not known whether<span class="Bold"> UROGESIC-BLUE™ </span>tablets cause fetal harm when administered to a pregnant woman or can affect reproduction capacity.<span class="Bold"> UROGESIC-BLUE™ </span>tablets should be given to a pregnant woman only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="section-7.3"></a><p></p>
<h2>Breast-feeding</h2>
<p class="First">problems in humans have not been documented; however, methenamine and traces of hyoscyamine are excreted in breast milk.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-7.4"></a><p></p>
<h2>Prolonged use</h2>
<p class="First">there have been no studies to establish the safety of prolonged use in humans. No known long-term animal studies have been performed to evaluate carcinogenic potential.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="section-7.5"></a><p></p>
<h2>Pediatric</h2>
<p class="First">infants and young children are especially susceptible to the toxic effect of the belladonna alkaloids.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="section-7.6"></a><p></p>
<h2>Geriatric</h2>
<p class="First">use with caution in elderly patients as they may respond to usual doses of hyoscyamine with <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, or <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="section-7.7"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">because of this product's effect on gastrointestinal motility and gastric emptying, it may decrease the absorption of other oral medications during concurrent use such as: urinary alkalizers; thiazide diuretics (may cause the urine to become alkaline reducing the effectiveness of methenamine by inhibiting its conversion to formaldehyde); antimuscarinics (concurrent use may intensify antimuscarinic effects of hyoscyamine because of secondary antimuscarinic activities of these medications); antacids/antidiarrheals (may reduce absorption of hyoscyamine, concurrent use with antacids may cause urine to become alkaline reducing effectiveness of methenamine by inhibiting its conversion to formaldehyde) doses of these medications should be spaced 1 hour apart from doses of hyoscyamine; antimyasthenics (concurrent use with hyoscyamine may further reduce intestinal motility); ketoconazole (patients should be advised to take this combination at least 2 hours after ketoconazole); monoamine oxidase (MAO) Inhibitors (concurrent use may intensify antimuscarinic side effects, opoid (narcotic) analgesics may result in increased risk of severe <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>); sulfonamides (these drugs may precipitate with formaldehyde in the urine, increasing the danger of <span class="product-label-link" type="condition" conceptid="4188213" conceptname="Crystalluria">crystalluria</span>).</p>
<p>Patients should be advised that the urine may become blue to blue green and the feces may be discolored as a result of the excretion of methylene blue.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First"><span class="Bold">Cardiovascular </span>– rapid pulse, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span></p>
<p><span class="Bold">Central Nervous System </span>– <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span></p>
<p><span class="Bold">Respiratory </span>– <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> or troubled breathing</p>
<p><span class="Bold">Genitourinary </span>– difficulty micturition, acute <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span></p>
<p><span class="Bold">Gastrointestinal </span>– <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span></p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="section-9"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First">A <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> on the use of<span class="Bold"> UROGESIC-BLUE™ </span>has not been reported and due to the nature of its ingredients, abuse of<span class="Bold"> UROGESIC-BLUE™ </span>is not expected.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<p class="First"><span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">Emesis</span> or gastric lavage. Slow intravenous administration of physostigmine in doses of 1 mg to 4 mg (0.5 mg to 1 mg in children), repeated as needed in one to two hours to reverse severe antimuscarinic symptoms. Administration of small doses of diazepam to control <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span> and <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>. Artificial respiration with oxygen if needed for <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. Adequate hydration. Symptomatic treatment as necessary.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1"></a><p></p>
<h2>Adults</h2>
<p class="First">One tablet orally 4 times per day followed by liberal fluid intake.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2"></a><p></p>
<h2>Older Children</h2>
<p class="First">Dosage must be individualized by physician. Not recommended for use in children up to 6 years of age.</p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First"><span class="Bold">UROGESIC-BLUE™ are light blue to blue, oval, biconvex tablets debossed with "ED UB" with scoreline on one side and plain on the other side. Supplied in bottles of 100 tablets (NDC 0485-0151-01).</span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-12.1"></a><p></p>
<h2>CAUTION</h2>
<p class="First">RX ONLY</p>
</div>
<div class="Section" data-sectionCode="44425-7">
<a name="section-12.2"></a><p></p>
<h2>STORAGE</h2>
<p class="First">Store at 25° C (77° F); excursions permitted to 15° C to 30° C (59° F to 86° F) (See USP Controlled Room Temperature). Keep container tightly closed.</p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13"></a><p></p>
<p class="First">Manufactured for:<br><span class="Bold">Edwards Pharmaceutical, Inc.<br> 111 W. Mulberry St. Ripley, Mississippi 38663</span></p>
<p>Manufactured by:<br><span class="Bold">Belcher Pharmaceuticals, LLC<br>Largo, FL 33777</span></p>
<p>May 2011                    R-0110B</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-14"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 100 count Tablet Bottle Label</h1>
<p class="First"><span class="Italics">NEW<br>FORMULATION</span></p>
<p>NDC 0485-0151-01</p>
<p><span class="Bold">UROGESIC-BLUE</span>™</p>
<p><span class="Bold">URINARY ANTISEPTIC<br>ANTISPASMODIC</span></p>
<p><span class="Bold">DESCRIPTION: </span>Each tablet contains:</p>
<table width="50%">
<col align="left" valign="top" width="70%">
<col align="right" valign="top" width="30%">
<tbody class="Headless">
<tr class="First Toprule">
<td align="left">Methenamine, USP</td>
<td align="right">81.6 mg</td>
</tr>
<tr>
<td align="left">Monobasic Sodium Phosphate, USP</td>
<td align="right">40.8 mg</td>
</tr>
<tr>
<td align="left">Methylene Blue, USP</td>
<td align="right">10.8 mg</td>
</tr>
<tr class="Botrule Last">
<td align="left">Hyoscyamine Sulfate, USP</td>
<td align="right">0.12 mg</td>
</tr>
</tbody>
</table>
<p><span class="Bold">CONTENTS: 100 TABLETS</span></p>
<p><span class="Bold">RX ONLY</span></p>
<p>Manufactured for<br><span class="Bold">EDWARDS<br>PHARMACEUTICAL, INC.</span><br>Ripley, MS 38663</p>
<div class="Figure"><img alt="PRINCIPAL DISPLAY PANEL - 100 count Tablet Bottle Label" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=f650dd78-615c-42d3-9b2d-3a989039d80c&amp;name=urogesic-01.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>UROGESIC BLUE 		
					</strong><br><span class="contentTableReg">methenamine, sodium phosphate, monobasic, methylene blue, and hyoscyamine sulfate tablet, coated</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0485-0151</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>METHENAMINE</strong> (METHENAMINE) </td>
<td class="formItem">METHENAMINE</td>
<td class="formItem">81.6 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>SODIUM PHOSPHATE, MONOBASIC</strong> (SODIUM CATION) </td>
<td class="formItem">SODIUM PHOSPHATE, MONOBASIC</td>
<td class="formItem">40.8 mg</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>METHYLENE BLUE</strong> (METHYLENE BLUE CATION) </td>
<td class="formItem">METHYLENE BLUE</td>
<td class="formItem">10.8 mg</td>
</tr>
<tr class="formTableRow">
<td class="formItem">
<strong>HYOSCYAMINE SULFATE</strong> (HYOSCYAMINE) </td>
<td class="formItem">HYOSCYAMINE SULFATE</td>
<td class="formItem">0.12 mg</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CELLULOSE, MICROCRYSTALLINE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>CROSCARMELLOSE SODIUM</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MAGNESIUM STEARATE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">BLUE (LIGHT BLUE) </td>
<td class="formLabel">Score</td>
<td class="formItem">2 pieces</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">OVAL</td>
<td class="formLabel">Size</td>
<td class="formItem">13mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem">ED;UB</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0485-0151-01</td>
<td class="formItem">100  in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">UNAPPROVED DRUG OTHER</td>
<td class="formItem"></td>
<td class="formItem">11/19/2010</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>EDWARDS PHARMACEUTICALS, INC.
							(195118880)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Belcher Pharmaceuticals, LLC</td>
<td class="formItem"></td>
<td class="formItem">965167955</td>
<td class="formItem">MANUFACTURE(0485-0151), ANALYSIS(0485-0151), PACK(0485-0151), LABEL(0485-0151)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 11/2010<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>10109075-6a32-4562-9dc8-c148a61d5d58</div>
<div>Set id: f650dd78-615c-42d3-9b2d-3a989039d80c</div>
<div>Version: 1</div>
<div>Effective Time: 20101130</div>
</div>
</div> <div class="DistributorName">EDWARDS PHARMACEUTICALS, INC.</div></p>
</body></html>
